Lexaria Bioscience Corp. Announces Progress on Animal Study and New Australian Patent Grant

Kelowna, British Columbia — June 23, 2026 — Leads & Copy — Lexaria Bioscience Corp. announced updates on Animal Study #1 (GLP-1-A26-1), which is examining formulation enhancements for glucagon-like peptide-1 (GLP-1) and CBD compositions using its DehydraTECH platform. The study aims to evaluate potential improvements in performance and establish new intellectual property claims.

Dosing for the study commenced on June 10, 2026, and results are anticipated by early September, barring any disruptions. A key objective of the study is to investigate novel alternative formulations to SNAC (salcaprozate sodium), the excipient used by Novo Nordisk in its oral GLP-1 products. Should Lexaria demonstrate similar or superior performance enhancements to SNAC, it could lead to valuable proprietary intellectual property and an alternative for the competitive GLP-1 market.

To this end, Lexaria has already filed three new patent applications related to technological advancements in this area. The study involves Sprague-Dawley rats across 11 separate arms, testing various new compositions. Blood samples are collected at multiple timepoints between 8 and 24 hours post-dosing to assess the pharmacokinetic performance of each composition. Additionally, the study will measure drug concentrations in the brain, as DehydraTECH has previously shown potential for enhanced absorption of active ingredients into brain tissue, a factor increasingly recognized as vital for GLP-1 drug efficacy due to its role in brain neurochemistry.

The study includes one reference arm using an existing DehydraTECH-semaglutide (DHT-sema) composition and another using an existing DehydraTECH-CBD (DHT-CBD) composition. Lexaria plans to utilize its extensive historical study data and these reference arms as baseline comparators to identify areas for improvement.

The study is fully funded through existing corporate resources. In separate news, Lexaria was granted its first Australian patent (#2023302884) on June 11, 2026, under its Family #21 – Pharmaceutical Compositions and Methods for Treating Hypertension. This marks the seventh patent in this family, with previous grants in the U.S. (3), Europe (1), and Japan (2). The patent is valid until April 25, 2043.

DehydraTECH™ is Lexaria's patented drug delivery platform technology designed to enhance oral drug absorption into the bloodstream, potentially reducing side effects and improving delivery across the blood-brain barrier. The company operates a licensed in-house research laboratory and holds a significant intellectual property portfolio with 66 granted patents and others pending globally.

Source: Lexaria Bioscience Corp.